Rate Video

EHA 2020 | Combining B-cell receptor antagonists and venetoclax in CLL

Richard Furman • 10 Jun 2020

Chronic Lymphocytic Leukemia Leukemia Acalabrutinib Ibrutinib Umbralisib Venetoclax Zanubrutinib

Richard Furman, MD, of the Weill Cornell Medical College, New York, NY, outlines the benefit of combining B-cell receptor antagonist and venetoclax to provide a synergistic effect in chronic lymphocytic leukemia (CLL). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

BTK inhibtors in CLL

Richard Furman • 10 Jun 2020

Acalabrutinib monotherapy in mature B-cell malignancies

Richard Furman • 10 Jun 2020

Diagnosis and Initial Treatment of CLL

Peter Hillmen et al. • 12 May 2017

Related Videos

Impact of MMRD and ELN genetic classification in outcomes for patients with AML underoging alloHCT

Muhammad Husnain • 17 Feb 2021

SIERRA trial updates: apamistamab in AML

Tania Jain • 12 Feb 2021

CAR-T vs. BiTEs in B-cell malignancies

Marion Subklewe • 11 Feb 2021

Flotetuzumab as salvage therapy for primary induction failure and early AML

Ibrahim Aldoss • 11 Feb 2021